Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Triumvira Immunologics

Request full access

At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease

San Francisco, United StatesFounded 2015Biotech & Life Sciences

About Triumvira Immunologics

Triumvira is a biotech startup that operates in the field of cancer treatment. The company's primary focus is on developing and commercializing a proprietary technology known as T cell Antigen Coupler (TAC). This technology is designed to enhance the body's natural defenses against cancer by empowering T cells, a type of white blood cell, to recognize, activate, and signal the destruction of cancer cells.

The TAC technology works by enabling T cells to target cancer cells using different antigens, which are substances that trigger an immune response. This means that the technology has broad applicability and could potentially be used to treat a wide range of both liquid and solid tumors.

Triumvira's business model revolves around the development and commercialization of this technology. The company is investing in advanced manufacturing technologies to ensure the optimum quality of its products. It is also building a robust pipeline of TAC-T cell therapies, with several programs currently in the preclinical and clinical trial stages.

Triumvira's potential clients are primarily patients with difficult-to-treat tumors. The company aims to improve the immune response of these patients and enhance their chances of survival.

In terms of revenue generation, Triumvira likely aims to make money by selling its TAC-T cell therapies to healthcare providers or directly to patients, once they have been approved for use by regulatory authorities.

Source: Dealroom company data

At a glance

Status
Operational
Employees
24
Open positions
None listed
Dealroom signal
32.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Mar 2022 $45M $275M Leaps by Bayer · ATEM Capital · Myeloma Investment Fund · Northpond Ventures ↗
SERIES AOther financing Aug 2020 $55M $220M Bloom Burton · Oceanpine Capital · Viva Vision Biotech · Leaps by Bayer —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Triumvira Immunologics website traffic

Latest recorded traffic for Triumvira Immunologics is 3K monthly website visits, up 150% over the last three months. Triumvira Immunologics's team declined 4% over the past year.

Latest monthly visits3K 3-month web change+150% 1-year team growth-4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Triumvira Immunologics in the San Francisco ecosystem

Live from Dealroom

The Triumvira Immunologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Leaps by Bayer
  • Northpond Ventures
  • Bloom Burton
  • Oceanpine Capital
  • Viva Vision Biotech
  • C3i
  • B Capital
  • ATEM Capital
  • Myeloma Investment Fund
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States73.3%
🇨🇦 Canada20%
🇨🇾 Cyprus6.7%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Triumvira Immunologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Triumvira Immunologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.